Monitor for EQ504 Phase 1 proof-of-mechanism data expected in Q2 2027, which will inform the planned proof-of-concept study in ulcerative colitis. The $20M financing triggered by first patient dosing removes near-term funding risk.
Drug in focus
EQ drug pipeline →EQ504
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1
- Time to market
- Unknown — the drug is in Phase 1 healthy-volunteer testing. If successful through Phase 2 and Phase 3, potential approval would be several years away (likely 2029-2031 at the earliest).
- Next catalyst
- None dated
What to watchThe next hard catalyst is topline Phase 1 proof-of-mechanism data in Q2 2027 (~6 months from now). Positive data showing AhR target engagement and a clean safety profile in healthy volunteers would validate the mechanism and support advancement into a Phase 2 proof-of-concept study in ulcerative colitis patients in H2 2027. Negative safety signals or failure to demonstrate target engagement would severely damage the thesis for a company now entirely dependent on EQ504 after its prior lead failed Phase 3.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 13 $1.29entry
- T+1 · 6d ago −10.85%α −8.94% · $1.15
- T+5 · 2d ago −17.83%α −9.27% · $1.06
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The key event is the initiation of a Phase 1 trial for lead candidate EQ504, with proof-of-mechanism data expected in Q2 2027, and a $20M milestone financing closed in October 2026, extending cash runway into 2029.
Key Facts
- First participant dosed in Phase 1 clinical trial of EQ504 in October 2026; proof-of-mechanism data expected Q2 2027
- Closed second tranche of August 2025 private placement for $20M gross proceeds on October 26, 2026
- Cash and cash equivalents $53.3M as of September 30, 2026; pro forma $72.0M including October financing
- Cash runway expected into 2029
- R&D expenses $2.5M in Q3 2026 vs $1.3M in Q3 2025; G&A $2.6M vs $3.3M
Financial Impact
Net loss of $4.6M in Q3 2026; cash position $53.3M ($72.0M pro forma); $20M milestone financing closed in October 2026
Risk Factors
- Clinical-stage biotech with no approved products; EQ504 Phase 1 data may not support advancement
- Net loss widened year-over-year as R&D spending increased for EQ504 development
- Dependence on successful clinical development of single lead candidate EQ504
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-458379 |
| Document: eq-ex99_1.htm | 0001193125-26-458379 |
| Document: 0001193125-26-458379-index-headers.html | 0001193125-26-458379 |
| Document: 0001193125-26-458379-index.html | 0001193125-26-458379 |
| Document: 0001193125-26-458379.txt | 0001193125-26-458379 |
| 8-K Data (Synthetic) | 0001193125-26-458379 |
Track record
20 reports on EQ
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +20.40% at T+60 after the Jun 5, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 20, 20262d ago EFFECT Neutral 4/10 Entry $1.12 Now $1.06 −5.36% settles Nov 23
- Nov 16, 20265d ago SC 13G/A Neutral 3/10 Entry $1.21 to $1.10 Now $1.06 −12.40% ▼ −9.09% −8.79% vs SPY
- Nov 13, 20268d ago SC 13G/A Neutral 2/10 Entry $1.15 to $1.21 Now $1.06 −7.83% ▲ +5.22% +6.23% vs SPY
- Nov 12, 20269d ago S-3 Neutral 4/10 Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
- Nov 12, 20269d ago 8-K Neutral 5/10 Viewing Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
- Nov 12, 20269d ago SC 13G/A Neutral 2/10 Entry $1.32 to $1.29 Now $1.06 −19.70% ▼ −2.27% −1.91% vs SPY
- Nov 4, 202617d ago SC 13G/A Neutral 2/10 Entry $1.40 to $1.33 Now $1.06 −24.29% ▼ −5.00% −0.59% vs SPY
- Oct 26, 202626d ago 8-K Bearish 6/10 Entry $1.36 to $1.42 Now $1.06 +22.06% ▼ −4.41% −4.07% vs SPY
- Oct 26, 202626d ago Press Release Neutral 4/10 Entry $1.25 to $1.36 Now $1.06 −15.20% ▲ +8.80% +8.24% vs SPY
- Oct 5, 20266w ago 8-K Neutral 3/10 Entry $1.42 to $1.39 Now $1.06 −25.35% ▼ −2.11% −1.87% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers